Containment Immune Response In-Vivo Research 
Pharmaceutical Technology
SEPTEMBER 14, 2022
As an autologous cell therapy, manufacturing the infusion product is a highly specialised process involving tumour harvest and the extraction and large-scale ex vivo expansion of TILs. Numerous academic and pharma-led studies have investigated the efficacy of TILs in the melanoma setting, with response rates ranging from very low to 50%.
The Pharma Data
APRIL 8, 2022
Now, new research from the Wyss Institute at Harvard University has revealed that this constant pattern of stretching and relaxing does even more – it generates immune responses against invading viruses. a Wyss Technology Development Fellow at the Institute. a Wyss Technology Development Fellow at the Institute.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
OCTOBER 21, 2022
The last month has seen a number of leaps in our understanding of difficult to treat and treatment resistant breast cancers, so here are Drug Discovery World’s top 5 research breakthroughs. In a scientific first, researchers at Penn State successfully 3D bioprinted breast cancer tumours and treated them.
The Pharma Data
APRIL 22, 2023
A key driver of MS is the sudden inflammation of nerves caused by so-called myeloid cells of the “innate” immune system in vulnerable regions of the brain and spinal cord, which together form the central nervous system (CNS). million individuals that currently have to live with the disease.
The Pharma Data
APRIL 22, 2023
The current COVID-19 vaccines are designed to trigger an antibody response to the SARS-CoV-2 spike protein, which is vulnerable to mutations that could make the vaccine less effective over time. In their study, the researchers challenged mice with a lethal dose of SARS-CoV-2 and found that 87.5%
The Pharma Data
DECEMBER 10, 2020
In the study, immunization with the hAd5-COVID-19 vaccine inhibited SARS-CoV-2 virus replication in 100% (10 of 10) of Rhesus macaques, with a drop in viral replication starting on the first day of vaccine administration, and undetectable viral levels as early as three to five days post-challenge in most of the animals.
The Pharma Data
JANUARY 11, 2021
Xiaomin Fan, Founder, President and CEO of AvantGen, “Even with the recent Emergency Use Authorization of multiple vaccines, we believe there remains an urgent need for potent antibody therapies and prophylactics for immunocompromised patients who cannot mount an adequate immune response either to the vaccine or to subsequent viral infection.
Expert insights. Personalized for you.
246 
Let's personalize your content